PON3 and prostate cancer: A meta‐analysis showed that PON3 was down‐regulated in hepatocellular carcinoma, renal clear cell sarcoma, ovarian serous papillary carcinoma, cervical cancer, papillary thyroid carcinoma, prostate cancer, and non‐Hodgkin lymphoma and up‐regulated in lung adenocarcinoma and pancreatic cancer [25, 26].